Search

Displaying results 3831 - 3840 of 4231 in total
  1. Drug

    Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)

    go.drugbank.com/drugs/DB15863
    Experimental

    As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538).

  2. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

  3. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  4. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome.

  5. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate

  6. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and ...

  7. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...

  8. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  9. Drug

    5-fluorouridine

    go.drugbank.com/drugs/DB01629
    Investigational

    5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid.

  10. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual